UrologyNews.net

Urology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
Farmaexplorer.it

Search results for "Xtandi"

The androgen receptor inhibitor, Enzalutamide ( Xtandi ) is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on Docetaxel. A study has assessed the ac ...


The results from the phase 2 TERRAIN trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in metastatic castration-resistant prostate cancer ( CRPC ) are published in the Lancet Oncol ...


The results from the STRIVE trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in men with castration-resistant prostate cancer ( CRPC ) are published in the Journal of Clinical Onc ...


In a phase III clinical trial, the hormone therapy Enzalutamide ( Xtandi ) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation thera ...


The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide ( Xtandi; n = 933 ) versus placebo ( n = 468 ) in asymptomatic men wi ...


Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic castration refractory prostate cancer ( mCRPC ). Per SW ...